Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Rx Regs Will Be Final By February, CMS Says

Executive Summary

The Medicare Part D regulations will need to be made final by February to give prescription drug plan sponsors adequate time to make bids for participation, Centers for Medicare & Medicaid Services Division of Plan Policy Director Thomas Hutchinson said

You may also be interested in...

USP Model Is “Starting Point”; CMS Formulary Standards Will Be True Test

U.S. Pharmacopeia's model drug classification system is only a "starting point" in developing a Medicare formulary that will pass muster with the Centers for Medicare & Medicaid Services

Medicare Rx Implementing Regs Open For Comment

CMS' schedule for the Medicare prescription drug benefit implementing regulations will give the agency 15 weeks to review comments and finalize the rule before Inauguration Day

Kerry/Edwards Medicare Rx “Overhaul” Plan: Negotiation, Not Dictation

Democratic presidential candidate John Kerry's plans to "overhaul" the Medicare Rx legislation would not involve direct price setting by the federal government, Kerry Campaign Policy Director Sarah Bianchi maintained during the Banc of America Washington Health Care Conference July 7





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts